Aricept solid for Eisai ahead of key US expiry
This article was originally published in Scrip
Executive Summary
Total net sales at Eisai rose by 5% to ¥204.5 billion ($2.34 billion) in the first quarter to 30 June, driven by Aricept (donepezil) but constrained by the strength of the yen and a continued fall in US sales of Aciphex (rabeprazole).